W1 Emerging Vaccine Strategies & Technologies

Paula Bryant (NIAID), Donald Drake (Sanofi Pasteur VaxDesign Corp.), Klaus Frueh (Vaccine & Gene Therapy Institute), Johan Neyts (University of Leuven)



  • English

Publication year





  • Global initiatives

Topic references


P3.2 Developing Country Vaccine Manufacturers - Access to ImmunizationLakshminarayana Neti2018PresentationEnglish
*Meeting report: Global vaccine and immunization research forum, 2018Angela Hwang, B. Fenton Hall, Martin Friede, Peter Dull2019Journal articleEnglish
Agenda - GVIRF 2018GVIRF Secretariat2018PresentationEnglish
Introduction to GVIRFB. Fenton Hall2018PresentationEnglish
KN1 Beyond effectiveness: research on vaccines seen as a continuumAlejandro Cravioto2018PresentationEnglish
KN2 National and regional capacity for biotechnology research; Indian experienceMaharaj Kishan Bhan2018PresentationEnglish
P1 Progress Towards and Commonalities in Vaccine Development Against HIV, TB, and MalariaMary Marovich2018ReportEnglish
P1.1 Advanced Clinical Development of HIV VaccinesK. T. Mngadi2018PresentationEnglish
P1.2 Commonalities across vaccine development effortsPunnee Pitisuttithum2018PresentationEnglish
P1.3 Progress towards vaccines against TBGerald Voss2018PresentationEnglish
P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine developmentFred Binka2018PresentationEnglish
P1.5 Gaps in Malaria VaccinesJ. Kevin Baird2018PresentationEnglish
P2 Innovating for EquityNarendra Arora2018ReportEnglish
P2.1 Intensified Mission Indradhanush: Addressing Equity in ImmunizationPradeep Haldar2018PresentationEnglish
P2.2 Use of Multiple Measures for Immunization Management in Migratory PopulationLin Luan2018PresentationEnglish
P2.4 Social Media Initiative in Ukraine: Analysis of Conversations on Polio, Vaccination and Routine ImmunizationAnna Postovoitova2018PresentationEnglish
P2.5 Universal Health Coverage: a people-centred approachBirgitte Giersing2018PresentationEnglish
P2.6 Strengthening Vaccination Programs among the Urban Poor: Closing the Equity GapFolake Olayinka2018PresentationEnglish
P3 Growing Developing Country Vaccine ManufactureA. A. Adeyemo2018ReportEnglish
P3.1 Vaccine Production in Developing Countries: an Economic EvaluationSyarifah Liza Munira2018PresentationEnglish
P3.3 Vaccine Manufacturing in Developing Countries: Perspectives on Approaches to Take, and Factors to Consider, towards Sustainable Manufacturing CapacityMartin Nicholson2018PresentationEnglish
P3.4 Addressing Patent Barriers to Vaccine Development & AccessKate Elder2018PresentationEnglish
P4 Regulatory Capacity, Challenges, and ConvergencesNorman W. Baylor2018ReportEnglish
P4.1 Alternative Regulatory Pathways: Opportunities and ChallengesNorman W. Baylor2018PresentationEnglish
P4.2 Benefits and Challenges: How regulators can reduce time and efforts in the case of public health emergencies?Yeowon Sohn2018PresentationEnglish
P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from ThailandAkanid Wapeewuttikorn2018PresentationEnglish
P5 Evidence for Decision MakingDavid Kaslow, Robert BreimanReportEnglish
P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseasesDavid Kaslow2018PresentationEnglish
P5.2 Evidence for Decision MakingYot Teerawattananon2018PresentationEnglish
P6 Polio Endgame: Needs and OpportunitiesRoland SutterReportEnglish
P6.1 Intro Polio Endgame: Needs and OpportunitiesRoland Sutter2018PresentationEnglish
P6.2 Global tOPV withdrawal: "The Switch" experienceAlejandro Ramirez Gonzalez2018PresentationEnglish
P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?Ondrej Mach2018PresentationEnglish
P6.4 Polio Vaccines - R&D UpdatesPeter Dull2018PresentationEnglish
P6.5 Research for polio policy making: Lessons learnedRoland Sutter2018PresentationEnglish
P7 Discussion with Thought LeadersPeter Dull2018ReportEnglish
W1 Emerging Vaccine Strategies & TechnologiesPaula Bryant2018ReportEnglish
W1.1 MIMIC: an in vitro model of human immunityDon Drake2018PresentationEnglish
W1.2 New Vaccine Strategies using cytomegalovirusKlaus Früh2018PresentationEnglish
W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) VaccinesJohan Neyts, Kai Dallmeier2018PresentationEnglish
W2 R&D Update: Enteric VaccinesGagandeep Kang, Jean-Pierre Amorij2018ReportEnglish
W2.1 An update on rotavirus vaccinesGagandeep Kang2018PresentationEnglish
W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccinesCal MacLennan2018PresentationEnglish
W2.3 Controlled Human Infection Models and Enteric Vaccine DevelopmentBeth Kirkpatrick2018PresentationEnglish
W3 Pneumococcal Vaccines: Lessons Learned and the Road AheadHani Kim2018ReportEnglish
W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and ImpactKatherine L. O'Brien2018PresentationEnglish
W3.2 Rollout of Pneumococcal Conjugate Vaccine in IndiaNarendra K Arora, Pradeep Haldar2018PresentationEnglish
W3.3 The Future of Pneumococcal Conjugate VaccinesKeith Klugman2018PresentationEnglish
W4 Immunological Principles of Vaccines and VaccinationAnnie Mo, Bernhards Ogutu2018ReportEnglish
W4.1 New Approaches to Understanding Human ImmunityAnnie Mo2018PresentationEnglish

Added by: Angela Hwang

Added on: 2022-02-15 12:23:55

Hits: 678

Uploaded file


Click to Download